Asset profile
Baxdrostat · Baxfendy
Small molecule
Evidence outlook
Approved: Hypertension (label: adults not adequately controlled on other agents, in combination)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Chronic Kidney Disease · Phase 3Heart Failure · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
168 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 162 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Baxdrostat (Baxfendy): this drug | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Lorundrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Vicadrostat | Phase 3 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| QLS1410 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| SAL0140 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| VB19055 | Phase 2 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| JX09 | Phase 1 | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) |
…and 153 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
August 2027 (1)
What to watch
2028 (4)
February 2028 (2)
May 2028 (1)
What to watch
June 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.